Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-096255
Filing Date
2025-10-06
Accepted
2025-10-03 21:16:29
Documents
52
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0259852-6k_nlspharm.htm   iXBRL 6-K 16742
2 UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS OF NLS PHARMACEUTICS LTD. AS OF ea025985201ex99-1_nlspharm.htm   iXBRL EX-99.1 452177
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea025985201ex99-2_nlspharm.htm EX-99.2 96444
  Complete submission text file 0001213900-25-096255.txt   4076835

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20250630.xsd EX-101.SCH 43987
5 XBRL CALCULATION FILE nlsp-20250630_cal.xml EX-101.CAL 29379
6 XBRL DEFINITION FILE nlsp-20250630_def.xml EX-101.DEF 216096
7 XBRL LABEL FILE nlsp-20250630_lab.xml EX-101.LAB 413337
8 XBRL PRESENTATION FILE nlsp-20250630_pre.xml EX-101.PRE 234320
55 EXTRACTED XBRL INSTANCE DOCUMENT ea0259852-6k_nlspharm_htm.xml XML 387320
Mailing Address THE CIRCLE 6 8058 ZURICH Switzerland
Business Address THE CIRCLE 6 8058 ZURICH Switzerland 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 251375487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)